Compare Alcon AG (ALC) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while iShares 3 7 Year Treasury Bond ETF trades at $116.63. The key difference: Alcon AG pays a 0.54% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Alcon AG is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ALC | IEI | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Fixed Income |
52-Week High | $92.22 | $120.72 |
52-Week Low | $62.02 | $116.67 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $117.20 with minimal daily movement (+0.08%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. The ETF focuses exclusively on intermediate-term U.S. Treasury debt, offering lower volatility compared to corporate bond alternatives. Recent dividend payments of $0.36-$0.37 demonstrate consistent income distribution to investors.
The outlook for IEI remains heavily dependent on Federal Reserve policy direction amid ongoing inflation concerns. While Treasury-focused ETFs provide safety during market volatility, rising rate expectations pose headwinds for bond prices. The fund's government debt exposure offers stability but may underperform higher-yielding alternatives in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
